Selank & Semax: Russia's Approved Nootropic Peptides

Development History

The story of Selank and Semax begins in the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow during the 1980s. Two research groups, led by some of Russia's most distinguished neuroscientists, set out to develop peptide-based cognitive enhancers that could match or exceed the efficacy of synthetic nootropics and anxiolytics — without their side effects.

Both peptides were developed by taking naturally occurring peptide fragments from the human body and modifying them for enhanced stability and bioavailability. After decades of preclinical and clinical research, both received regulatory approval in Russia for clinical use:

• Semax: Approved in 1996 as a nootropic and neuroprotective agent
• Selank: Approved in 2009 as an anxiolytic agent

Together, they represent over 40 years of cumulative research, with thousands of published studies in Russian-language and English-language peer-reviewed journals.

Selank: Anxiolytic Without Sedation

Structure and Origin

Selank is a synthetic analogue of tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by enzymatic cleavage of immunoglobulin G in the spleen. Tuftsin is a potent immune modulator that enhances phagocytosis, natural killer cell activity, and T-cell function.

Selank extends tuftsin with a stabilising Pro-Gly-Pro sequence at the C-terminus, creating a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) with dramatically improved stability and bioavailability.

Mechanism of Action

Selank operates through multiple complementary pathways:

• GABA modulation: Enhances GABAergic transmission without directly binding GABA receptors (unlike benzodiazepines). This produces anxiolytic effects without sedation, cognitive impairment, or dependence.
• BDNF upregulation: Increases brain-derived neurotrophic factor expression in the hippocampus and prefrontal cortex — supporting learning, memory, and neuroplasticity.
• Serotonin modulation: Influences serotonin metabolism and receptor sensitivity, contributing to mood stabilisation.
• Enkephalin system: Modulates endogenous opioid peptides, providing stress resilience without euphoria or addiction potential.
• Immune modulation: Retains tuftsin's immune-enhancing properties — increases IL-6, enhances phagocyte activity, and normalises immune function.

Clinical Evidence

Over 20 years of clinical use in Russia have demonstrated:

• Anxiety reduction comparable to benzodiazepines, without sedation, tolerance, or withdrawal
• Cognitive enhancement in attention, working memory, and information processing
• Immune normalisation in patients with anxiety-related immune suppression
• Neuroprotection in models of ischaemic stroke and neurodegenerative disease
• No adverse effects at therapeutic doses across decades of clinical monitoring

Semax: Cognitive Enhancement Without Stimulant Side Effects

Structure and Origin

Semax is a synthetic analogue of ACTH(4-10) — a seven-amino-acid fragment of adrenocorticotropic hormone (Met-Glu-His-Phe-Pro-Gly-Pro). ACTH(4-10) was known since the 1960s to have cognitive-enhancing properties independent of its adrenal effects.

The Pro-Gly-Pro C-terminal extension stabilises the molecule against enzymatic degradation, extending its half-life from minutes to several hours.

Mechanism of Action

Semax is one of the most potent known BDNF upregulators:

• BDNF expression: Semax increases BDNF mRNA expression by up to 5–8 fold in the hippocampus and cortex — one of the largest increases documented for any compound.
• NGF upregulation: Also increases nerve growth factor, supporting cholinergic neurons critical for memory.
• Dopamine modulation: Enhances dopaminergic transmission in the prefrontal cortex and striatum, improving motivation, focus, and working memory. Unlike amphetamines, it does not cause dopamine depletion or crash.
• Serotonin modulation: Normalises serotonergic function, contributing to mood stability.
• Neuroprotection: Reduces oxidative stress, stabilises mitochondrial function in neurons, and inhibits excitotoxicity.

Clinical Evidence

• Stroke recovery: Approved in Russia for treatment of ischaemic stroke. Clinical studies showed improved recovery of motor function, speech, and cognitive abilities when administered within the first 12 hours.
• Cognitive enhancement: Healthy volunteers show improved attention, short-term memory, and cognitive flexibility.
• ADHD: Studies show improvement in attention metrics without stimulant side effects.
• Optic nerve disease: Approved for glaucoma and optic nerve atrophy — the neurotrophic effects protect and regenerate optic nerve fibres.
• No stimulant side effects: No insomnia, appetite suppression, cardiovascular stress, or crash.

Comparison Table

Feature	Selank	Semax
Origin	Tuftsin (immune peptide)	ACTH(4-10) (neuroendocrine)
Primary effect	Anxiolytic + nootropic	Nootropic + neuroprotective
BDNF increase	Moderate (2–3x)	High (5–8x)
Anxiety reduction	Primary indication	Secondary benefit
Focus/attention	Moderate improvement	Significant improvement
Immune effects	Strong (tuftsin heritage)	Mild
Stroke recovery	Not indicated	Approved indication
Sedation	None	None
Dependence risk	None	None
Russian approval	2009	1996

Administration: Intranasal vs Subcutaneous

Both peptides are available in intranasal and subcutaneous formulations:

Intranasal

• Advantages: Non-invasive, rapid onset (15–30 minutes), bypasses first-pass metabolism, direct access to CNS via olfactory neurons
• Disadvantages: Variable absorption depending on nasal mucosa condition, lower total bioavailability

Subcutaneous

• Advantages: Consistent bioavailability, precise dosing, reliable absorption
• Disadvantages: Requires injection, slightly slower onset

For cognitive enhancement, intranasal administration is the most common route due to convenience and direct CNS access. For immune modulation (Selank), subcutaneous may be preferred for more consistent systemic delivery.

Practical Protocols

Selank Protocol (Anxiety + Cognitive Support)

• Dose: 250–500 mcg intranasal, 2–3 times daily; or 250–500 mcg subcutaneous once daily
• Cycle: 2–4 weeks on, 1–2 weeks off (though continuous use has shown no tolerance)
• Best for: Generalised anxiety, stress resilience, immune support, mild cognitive enhancement

Semax Protocol (Cognitive Enhancement)

• Dose: 200–600 mcg intranasal, 1–2 times daily; or 200–400 mcg subcutaneous once daily
• Cycle: 2–4 weeks on, 1–2 weeks off
• Best for: Focus, learning, memory, creative work, stroke recovery, neuroprotection

Combining Selank + Semax

Many users combine both peptides for comprehensive cognitive enhancement:

• Morning: Semax 300–600 mcg intranasal (focus, dopamine, BDNF)
• Afternoon/Evening: Selank 250–500 mcg intranasal (anxiolytic, stress reduction, immune support)

This combination provides daytime cognitive sharpness with underlying anxiety reduction and stress resilience — without any stimulant crash, sedation, or dependence.

The Bottom Line

Selank and Semax are not experimental compounds. They are clinically approved medications with decades of human use data, developed through rigorous academic research at one of Russia's premier scientific institutions. They represent a fundamentally different approach to cognitive enhancement — working with the brain's own neurotrophic and modulatory systems rather than forcing neurotransmitter imbalances.

Mito Labs offers pharmaceutical-grade Selank and Semax in both intranasal and injectable formulations. All products undergo third-party testing for identity, purity, sterility, and endotoxin levels.